Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer

被引：0
|
作者：
Joyce O’Shaughnessy
Adam Brufsky
Hope S. Rugo
Sara M. Tolaney
Kevin Punie
Sagar Sardesai
Erika Hamilton
Delphine Loirat
Tiffany Traina
Roberto Leon-Ferre
Sara A. Hurvitz
Kevin Kalinsky
Aditya Bardia
Stephanie Henry
Ingrid Mayer
Yanni Zhu
See Phan
Javier Cortés
机构：
[1] Texas Oncology-Baylor Charles A. Sammons Cancer Center,Medical Oncology
[2] University of Pittsburgh Medical Center,Magee
[3] University of California San Francisco Helen Diller Family Comprehensive Cancer Center,Womens Hospital and the Hillman Cancer Center
[4] Dana-Farber Cancer Institute,Department of Medicine
[5] Leuven Cancer Institute,Medical Oncology
[6] University Hospitals Leuven,Department of General Medical Oncology and Multidisciplinary Breast Centre
[7] The Ohio State University Comprehensive Cancer Center,Medical Oncology Department and D3i
[8] Sarah Cannon Research Institute/Tennessee Oncology,Department of Oncology
[9] Institut Curie,Medical Oncology
[10] Memorial Sloan Kettering Cancer Center,Department of Hematology/Oncology
[11] Mayo Clinic,Department of Oncology
[12] University of California,Hematology, Radiotherapy, and Nuclear Medicine
[13] Los Angeles,Breast Cancer Program, Division of Hematology/Oncology
[14] Jonsson Comprehensive Cancer Center,Department of Biostatistics
[15] Columbia University Irving Medical Center,Department of Clinical Development
[16] Massachusetts General Hospital Cancer Center,International Breast Cancer Center
[17] Harvard Medical School,undefined
[18] CHU UCL Namur,undefined
[19] Vanderbilt-Ingram Cancer Center,undefined
[20] Gilead Sciences,undefined
[21] Inc.,undefined
[22] Gilead Sciences,undefined
[23] Inc.,undefined
[24] Quironsalud Group,undefined
[25] Winship Cancer Institute,undefined
[26] Emory University,undefined
来源：
Breast Cancer Research and Treatment | 2022年 / 195卷
关键词：
Sacituzumab govitecan; Antibody–drug conjugate; Cyclin-dependent kinase inhibitor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：127 / 139
页数：12
相关论文
共 50 条
  • [41] Assessment of sacituzumab govitecan (SG) in patients (pts) with prior neoadjuvant/adjuvant chemotherapy in the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC)
    Hegewisch-Becker, S.
    Loirat, D. L.
    Punie, K.
    Bardia, A.
    Dieras, V
    Dalenc, F.
    Diamond, J. R.
    Fontaine, C.
    Wang, G.
    Rugo, H. S.
    Hurvitz, S. A.
    Kalinsky, K.
    O'Shaughnessy, J.
    Carey, L. A.
    Loibl, S.
    Gianni, L.
    Piccart, M.
    Hong, Q.
    Phan, S.
    Itri, L. M.
    Cortes, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 133 - 133
  • [42] Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer (vol 8, 98, 2022)
    Rugo, Hope S.
    Tolaney, Sara M.
    Loirat, Delphine
    Punie, Kevin
    Bardia, Aditya
    Hurvitz, Sara A.
    O'Shaughnessy, Joyce
    Cortes, Javier
    Dieras, Veronique
    Carey, Lisa A.
    Gianni, Luca
    Piccart, Martine J.
    Loibl, Sibylle
    Goldenberg, David M.
    Hong, Quan
    Olivo, Martin
    Itri, Loretta M.
    Kalinsky, Kevin
    NPJ BREAST CANCER, 2024, 10 (01)
  • [43] Metastatic Triple-negative Breast Cancer
    Rakha, E. A.
    Chan, S.
    CLINICAL ONCOLOGY, 2011, 23 (09) : 587 - 600
  • [44] Metastatic Triple-Negative Breast Cancer
    Zhang, Xiaojie
    Yeung, Kay T.
    CURRENT BREAST CANCER REPORTS, 2023, 15 (03) : 288 - 297
  • [45] Metastatic Triple-Negative Breast Cancer
    Xiaojie Zhang
    Kay T. Yeung
    Current Breast Cancer Reports, 2023, 15 : 288 - 297
  • [46] Health-related quality of life (HRQoL) in the ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC)
    Loibl, S.
    Loirat, D.
    Tolaney, S. M.
    Punie, K.
    Oliveira, M.
    Rugo, H. S.
    Bardia, A.
    Hurvitz, S. A.
    Brufsky, A.
    Kalinsky, K.
    Cortes, J.
    O'Shaughnessy, J.
    Dieras, V. C.
    Carey, L. A.
    Gianni, L.
    Gharaibeh, M.
    Moore, L.
    Shi, L.
    Piccart, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S472 - S473
  • [47] Exposure-Response Analyses of Sacituzumab Govitecan Efficacy and Safety in Patients With Metastatic Triple-Negative Breast Cancer
    Sathe, Abhishek G.
    Diderichsen, Paul M.
    Fauchet, Floris
    Phan, See-Chun
    Girish, Sandhya
    Othman, Ahmed A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2025, 117 (02) : 570 - 578
  • [48] Post-progression therapy outcomes in patients (pts) from the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC)
    Cortes, Javier
    Bardia, Aditya
    Loirat, Delphine
    Tolaney, Sara M.
    Punie, Kevin
    Oliveira, Mafalda
    Hurvitz, Sara A.
    Brufsky, Adam
    Sardesai, Sagar
    Kalinsky, Kevin M.
    Traina, Tiffany
    Hamilton, Erika
    O'Shaughnessy, Joyce
    Dieras, Veronique
    Carey, Lisa A.
    Piccart, Martine
    Loibl, Sibylle
    Rugo, Hope S.
    Zhu, Yanni
    Phan, See
    Gianni, Luca
    CANCER RESEARCH, 2022, 82 (04)
  • [49] Revolutionizing triple-negative metastatic breast cancer treatment: sacituzumab Govitecan's role in advancing chemotherapy
    Qureshi, Zaheer
    Jamil, Abdur
    Altaf, Faryal
    Siddique, Rimsha
    Fatima, Eeshal
    Dost, Sara
    Zelkowitz, Richard Scott
    Shah, Shivendra
    ANNALS OF MEDICINE AND SURGERY, 2024, 86 (09): : 5314 - 5319
  • [50] The European Medicines Agency review of sacituzumab govitecan for the treatment of triple-negative breast cancer
    Michaleas, S.
    Oliver, A. Moreno
    Mueller-Berghaus, J.
    Sarac, S. B.
    van der Elst, M. E.
    Mueller-Egert, S.
    Zander, H.
    Enzmann, H.
    Pignatti, F.
    ESMO OPEN, 2022, 7 (03)
12345